Skip to main content

Table 1 Summary of adverse events

From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

   Remogliflozin etabonate dose  
  Placebo 20 mg 50 mg 150 mg 500 mg 1000 mg Total
Healthy Subjects n = 10 n = 8 n = 8 n = 8 n = 8 n = 8 n = 10
  n (%) n (%) n (%) n (%) n (%) n (%) n (%)
At least one adverse event 4 (40) 2 (25) 3 (38) 1 (13) 3 (38) 1 (13) 8 (80)
Adverse events reported by >1 subject in total
Headache 1 (10) 1 (13) 1 (13) 0 2 (25) 1 (13) 4 (40)
Blood creatine phosphokinase increased 1 (10) 0 0 0 1 (13) 0 2 (20)
Drug-related adverse events
Headache 1 (10) 1 (13) 1 (13) 0 0 1 (13) 3 (30)
Dizziness 0 0 0 0 0 1 (13) 1 (10)
Diarrhea 0 1 (13) 0 0 0 0 1 (10)
Hot flush 0 0 0 0 0 1 (13) 1 (10)
T2DM subjects n = 6   n = 6   n = 6   n = 6
n (%) n (%) n (%) n (%)
At least one adverse event 3 (50) 1 (17) 2 (33) 4 (67)
Adverse events reported by >1 subject in total
Muscle cramp 1 (17)   1 (17)   0   2 (33)
β2-microglobulin increased 0   0   2 (33)   2 (33)
Drug-related adverse events
Nausea 0   0   1 (17)   1 (17)
β2-microglobulin increased 0   0   1 (17)   1 (17)
Pain in extremity 0   0   1 (17)   1 (17)
  1. n = number of subjects reporting event.
  2. % = percentage of subjects reporting event.